ArticleBMC neurology2026
Cognition and fatigue in clinically stable multiple sclerosis: EDSS and MRI metrics outperform serum biomarkers.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFatigue and cognitive impairment are common in multiple sclerosis (MS) affecting up to 95% and 65% of the patients, respectively. Only little is known about the interplay of different volumetric magnetic resonance imaging (MRI) parameters, the serum biomarkers neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP), cognition, and fatigue in MS patients without signs of progression independent of relapse activity (PIRA; i.e. clinically stable). This study aimed to evaluate whether volumetric MRI and serum NfL and GFAP are associated with cognitive impairment and fatigue in clinically stable relapsing-remitting multiple sclerosis (RRMS) and to examine whether the Expanded Disability Status Scale (EDSS) has an added value.
methodsA retrospective mono-centric cohort of 54 clinically stable (no disability worsening/relapse-free) RRMS patients underwent comprehensive clinical assessment with the EDSS, Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS-M), Fatigue Scale for Motor and Cognitive Functions (FSMC), in addition to established biomarkers of MS pathology, including sNfL, sGFAP, and magnetic resonance imaging (MRI: thalamic/hippocampal/whole brain parenchymal volumes/annualized brain volume loss (BVL/year)). Associations were examined using regressions, correlations, and group comparisons.
resultsThalamic and hippocampal volumes were significantly lower in cognitively impaired than non-impaired patients (both p<.001), while sNfL and sGFAP showed no group differences (p>.35; p>.09). Fatigue was not associated with MRI or serum markers (p>.09). BICAMS-M correlated with EDSS (r=–.56; p<.001) to a similar extent as with thalamic or hippocampal volumes (r=.55; p<.001). BVL/year was highly associated with cognitive impairment, explaining 63.2% (BICAMS-M) of the variance (p<.001).
conclusionIn our clinically stable, small RRMS cohort, BVL/year, thalamic and hippocampal volumes are associated with cognition in contrast to sNfL and sGFAP. EDSS as a global disability score correlates with cognition but adds little beyond MRI. These results require further validation using a prospective design and broader cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.